SOHO Italy 2022 | Clinical trials evaluating novel agents in MDS: SELECT-MDS-1
In this video, Giovanni Marconi, MD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the lack of therapies available for patients with myelodysplastic syndromes (MDS), and shares some insights into the SELECT MDS-1 trial (NCT04797780), which is evaluating tamibarotene plus azacitidine in patients with newly diagnosed RARA-positive MDS. Dr Marconi highlights that while MDS patients have primarily been treated with azacitidine and transplantation, tamibarotene may also improve peripheral recovery and complete remission (CR). This interview took place at the 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
